Outline:
Key Points
-
Google is striving to succeed in the artificial intelligence industry.
-
Micron is perhaps the largest AI value available.
-
Vertex Pharmaceuticals is expected to provide a lot of positive updates in 2026.
-
10 stocks that are more favorable than Vertex Pharmaceuticals ›
The higher the amount involved, the more thorough the investigation needs to be. Most investors wouldn’t be overly concerned if they lost $50. But losing $50,000 is a completely different situation.
Where can investors allocate such a significant sum without concern? Here are my recommendations for the top stocks to invest $50,000 in at this time.
1. Alphabet
Alphabet(NASDAQ: GOOG)(NASDAQ: GOOGL)has clearly shown that it is determined to succeed in the artificial intelligence (AI) market. Previously considered outdated by some in comparison to OpenAI’s ChatGPT, the company now asserts the top and second positions.large language models (LLMs)– Google Gemini 3.0 Pro and Google Gemini 3.0 Flash – ranked on LMArena’s AI model leaderboard.
This accomplishment not only provides Alphabet with a reason to be proud. I believe it will result in substantial revenue and profits for the company. More users are expected to opt for Google Cloud, which is currently the fastest-expanding among the leading three cloud services, to develop and implement their AI applications due to the features provided by Gemini.
Alphabet is also incorporating the newest and most advanced version of Gemini across its range of products. I anticipate this step will strengthen Google Search’s leading market position.
Investors should not ignore the significant opportunity Alphabet possesses through Waymo, as well. The self-driving car division holds a strong advantage in the robotaxi industry. I believe the potential of Waymo is not entirely captured in Alphabet’s current valuation.
2. Micron Technology
What’s the most significant AI deal currently? A strong argument can be made forMicron Technology(NASDAQ: MU).
Micron’s high-bandwidth memory (HBM) plays a vital role in AI chips. You don’t have to believe me. Here’s whatNvidia(NASDAQ: NVDA)CEO Jensen Huang stated last year: “Micron’s expertise in high-performance memory is essential for advancing the next wave of AI innovations that Nvidia is pioneering.” Lisa Su, CEO of Nvidia’s leading competitor,AMD(NASDAQ: AMD), also expressed favorable opinions about her company’s collaboration with Micron.
Is memory a commodity? Certainly. However, it is ahotcommodity. Micron’s CEO Sanjay Mehrotra disclosed last month that his company has completely allocated its HBM supply for the entire 2026 calendar year. He also forecasted a 40%compound annual growth ratefor HBM up to 2028, increasing from $35 billion in sales last year to $100 billion over the next three years.
Going back to Micron being a good deal, the stock is trading at aforward price-to-earnings ratio of 10.7 and a price-to-earnings-to-growth (PEG) ratioat 0.59. In my opinion, there is relatively little downside for Micron at this price, but significant potential for gains.
3. Vertex Pharmaceuticals
Not all top stocks to consider investing in at the moment are centered mainly on AI. I have praised the merits ofVertex Pharmaceuticals(NASDAQ: VRTX)For many years and continuing into 2026, expect Vertex to announce rapidly increasing sales of two new products during this year – Alyftrek and Journavx.
Alyftrek is the company’s strongest treatment for cystic fibrosis (CF) to date. Although it may reduce sales of older CF medications, this is acceptable. Vertex’s profits will still increase because Alyftrek carries a lower royalty cost. In the meantime, the non-opioid pain medication Journavx hasblockbusterscattered across it, in my opinion.
Vertex’s pipeline is also expected to bring positive developments. The major pharmaceutical company is currently in the process of submitting a rolling Biologics License Application (BLA) for povetacicept, which is intended for the treatment of IgA nephropathy. This long-term kidney condition impacts approximately 300,000 individuals in the U.S. and Europe. In contrast, CF – the indication that has contributed to Vertex’s success – affects about 109,000 people globally.
You could assume that these prospects are already reflected in Vertex’s stock price, given its forward earnings multiple of 25.4. Still, I don’t believe that’s accurate. The biotechnology stock’s PEG ratio, which considers five-year earnings growth estimates, stands at 0.58. I feel that Vertex, similar to Alphabet and Micron, has significant potential for further growth.
Is it a good time to invest in Vertex Pharmaceuticals?
Prior to purchasing shares in Vertex Pharmaceuticals, take this into account:
The Motley Fool Stock Advisorthe analysis team has recently recognized what they think are the10 best stocksFor investors to purchase now… and Vertex Pharmaceuticals was not among them. The 10 stocks that were selected have the potential to deliver significant gains in the years ahead.
Consider when Netflixcreated this list on December 17, 2004… if you had invested $1,000 at the time of our suggestion,you’d have $482,326!* Or when Nvidiacreated this list on April 15, 2005… if you had invested $1,000 at the time of our suggestion,you’d have $1,133,015!*
Now, it’s worth noting Stock Advisor’stotal average gain is 968% — a market-shattering outperformance compared to 197% for the S&P 500.Don’t overlook the newest top 10 ranking, available withStock Advisor, and become part of an investment group created by individual investors for the benefit of individual investors.
View the 10 stocks »
*Stock Advisor results as of January 11, 2026.
Keith Speightsholds shares in Alphabet and Vertex Pharmaceuticals. The Motley Fool holds positions in and advises on Advanced Micro Devices, Alphabet, Nvidia, and Vertex Pharmaceuticals. The Motley Fool has adisclosure policy.